Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Anastasios Konidaris - EVP & CFO Chirag Patel - Co-Founder, Co-CEO, President & Director Chintu Patel - Co-Founder, Co-CEO & Director Joseph Todisco - EVP & Chief Commercial Officer, Specialty Conference Call Participants Gregory Gilbert - Truist Securities Daniel Busby - RBC Capital Markets Ami Fadia - SVB Leerink David Amsellem - Piper Sandler & Co. Operator Good morning, and welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.01 per share AMRX New York Stock Exchange Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Delaware 32-0546926 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Amneal Pharma ...

Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) Q1 2020 Earnings Conference Call May 11, 2020 8:30 AM ET Company Participants Tasos Konidaris - SVP and CFO Chirag Patel - Co CEO and President Chintu Patel - Co CEO Conference Call Participants Greg Gilbert - SunTrust Randall Stanicky - RBC Balaji Prasad - Barclays Ami Fadia - SVB Leerink Elliot Wilbur - Raymond James David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Chris Schott - JPMorgan Operator Good morning and welcome to the Amneal Pharmaceuti ...

Financial Performance - Net revenue for 2019 was $1,626,373, a decrease from $1,662,991 in 2018, representing a decline of approximately 2%[242] - The net loss for 2019 was $603,573, compared to a net loss of $201,303 in 2018, reflecting an increase in losses of approximately 200%[242] - Total equity (deficit) decreased to $346,788 in 2019 from $896,363 in 2018, indicating a significant decline in equity[243] Expenses - Research and development expenses for 2019 totaled $202,287, down from $210,451 in 2018, indicating a reduction of about 4%[242] - The company incurred $173 million in charges related to the impairment of intangible assets in 2019, primarily due to the Combination[243] Assets and Liabilities - Total assets as of December 31, 2019, were $3,665,890, a decrease from $4,352,736 in 2018, representing a decline of about 16%[243] - Long-term debt, net, stood at $2,609,046 as of December 31, 2019, slightly down from $2,630,598 in 2018[243] Interest Rate Management - A hypothetical 1% increase in market interest rates could reduce the estimated fair value of the company's $2.7 billion variable rate debt by approximately $117 million[352] - The company entered into an interest rate lock agreement for a total notional amount of $1.3 billion, exchanging floating for fixed rate interest payments[353] Internal Control and Audit - Management concluded that internal control over financial reporting was effective as of December 31, 2019, based on the COSO criteria[361] - The company conducted its audit in accordance with PCAOB standards to ensure effective internal control over financial reporting[364] - The audit included assessing the risk of material weaknesses and evaluating the design and operating effectiveness of internal controls[365] - Internal control over financial reporting aims to provide reasonable assurance regarding the reliability of financial statements in accordance with GAAP[366] - Limitations of internal control may prevent or detect misstatements, and future evaluations are subject to risks of inadequacy[367] Code of Conduct - The company has adopted a Code of Business Conduct applicable to all employees, officers, and directors[370]

Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) Q4 2019 Earnings Conference Call February 26, 2020 8:30 AM ET Company Participants Steve Manzano - General Counsel and Corporate Secretary Chirag Patel - Co Chief Executive Officer and President Chintu Patel - Co Chief Executive Officer Todd Branning - Senior Vice President and Chief Financial Officer Joe Todisco - Senior Vice President of Specialty Commercial Conference Call Participants Elliot Wilbur - Raymond James David Amsellem - Piper Jaffray Greg Gilbert - Su ...